{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:40:57Z","timestamp":1771036857046,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.pharma.2023.03.003","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T12:40:43Z","timestamp":1679488843000},"page":"790-800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hypophosphor\u00e9mie apr\u00e8s traitement par fer injectable chez l\u2019adulte\u00a0: comparaison entre le carboxymaltose ferrique et l\u2019hydroxyde ferrique-saccharose"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6487-774X","authenticated-orcid":false,"given":"Michel","family":"Grino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Rigaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Violette","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Robert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Papailhau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-B\u00e9n\u00e9dicte","family":"Vincentelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10021","key":"10.1016\/j.pharma.2023.03.003_bib0560","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(15)60865-0","article-title":"Iron deficiency anaemia","volume":"387","author":"Lopez","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2023.03.003_bib0290","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00424-018-2231-z","article-title":"Physiological regulation of phosphate by vitamin D, parathyroid hormone (PTH) and phosphate (Pi)","volume":"471","author":"Jacquillet","year":"2019","journal-title":"Eur J Physiol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0295","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1152\/physrev.00002.2011","article-title":"Regulation and function of the FGF23\/Klotho endocrine pathways","volume":"92","author":"Martin","year":"2012","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharma.2023.03.003_bib0300","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ecl.2018.07.003","article-title":"Physiology of parathyroid hormone","volume":"47","author":"Goltzman","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.pharma.2023.03.003_bib0305","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ajh.25060","article-title":"Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: a randomized trial","volume":"93","author":"Adkinson","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0310","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/ajh.25564","article-title":"A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial","volume":"94","author":"Auerbach","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0315","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1007\/s11695-021-05858-0","article-title":"Efficacy and safety of ferric derisomaltose (FDI) compared with iron sucrose (IS) in patients with iron deficiency anemia after bariatric surgery","volume":"32","author":"Auerbach","year":"2022","journal-title":"Obes Surg"},{"key":"10.1016\/j.pharma.2023.03.003_bib0320","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/bcp.13189","article-title":"Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions","volume":"83","author":"Bager","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0325","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/172104","article-title":"Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency anemia: two randomized, controlled trials","author":"Barish","year":"2012","journal-title":"Anemia"},{"key":"10.1016\/j.pharma.2023.03.003_bib0330","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/ndt\/gfv096","article-title":"A randomized, open-label trial of isomaltoside 1000 (Monofer\u00ae) compared with iron sucrose (Venofer\u00ae) as maintenance therapy in haemodialysis patients","volume":"30","author":"Bhandari","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharma.2023.03.003_bib0335","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ndt\/gfaa011","article-title":"Safety and efficacy of iron maltoside 1000\/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open label, comparative trial","volume":"36","author":"Bhandari","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharma.2023.03.003_bib0340","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/jcph.1754","article-title":"Hypophosphatemia is common after intravenous ferric carboxymaltose infusion among patients with symptomatic heart failure with reduced ejection fraction","volume":"61","author":"Dashwood","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0345","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ajh.24633","article-title":"A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency","volume":"92","author":"Derman","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0350","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/apt.15386","article-title":"Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside","volume":"50","author":"Detlie","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.pharma.2023.03.003_bib0355","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.clinthera.2019.12.010","article-title":"Pharmacokinetic, pharmacodynamic, and safety profiles of ferric carboxymaltose in Chinese patients with iron-deficiency anemia","volume":"42","author":"Ding","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharma.2023.03.003_bib0360","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12916-020-01643-5","article-title":"Hypophosphatemia after high dose iron repletion with ferric carboxymaltose and ferric derisomaltose\u00a0\u2013\u00a0the randomized controlled HOMe aFers study","volume":"18","author":"Emrich","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.pharma.2023.03.003_bib0365","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1053\/j.gastro.2011.06.005","article-title":"FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease","volume":"141","author":"Evstatiev","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharma.2023.03.003_bib0370","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12876-020-01298-9","article-title":"Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status","volume":"20","author":"Fang","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0375","doi-asserted-by":"crossref","first-page":"e94217","DOI":"10.1371\/journal.pone.0094217","article-title":"Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women\u2013PREFER a randomized, placebo-controlled study","volume":"9","author":"Favrat","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharma.2023.03.003_bib0380","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ygh2.415","article-title":"Hypophosphataemia afer intravenous iron therapy with ferric carboxymaltose\u00a0\u2013\u00a0Real world experience from a tertiary centre in the UK","volume":"2","author":"Fragkos","year":"2020","journal-title":"GastroHep"},{"key":"10.1016\/j.pharma.2023.03.003_bib0385","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/468675","article-title":"Intravenous iron administration and hypophosphatemia in clinical practice","author":"Hardy","year":"2015","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0390","first-page":"1628","article-title":"A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy","volume":"33","author":"Huang","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharma.2023.03.003_bib0395","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12185-018-2400-z","article-title":"Pharmacokinetics, pharmacodynamics, safety, and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in Japanese volunteers with iron-deficiency anemia","volume":"107","author":"Ikuta","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0400","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12185-018-2501-8","article-title":"Comparison of efficacy and safety between intravenous ferric carboxymaltose and saccharated ferric oxide in Japanese patients with iron-deficiency anemia due to hypermenorrhea: a multi-center, randomized, open-label noninferiority study","volume":"109","author":"Ikuta","year":"2019","journal-title":"Int J Hematol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0405","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12884-019-2200-3","article-title":"Comparison of ferric carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy\u00a0\u2013\u00a0randomised controlled trial","volume":"19","author":"Jose","year":"2019","journal-title":"BMC Pregnancy Childbirth"},{"key":"10.1016\/j.pharma.2023.03.003_bib0410","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ijgo.2015.09.007","article-title":"Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding","volume":"133","author":"Mahey","year":"2016","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.pharma.2023.03.003_bib0415","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/ndt\/gft251","article-title":"Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial","volume":"29","author":"Onken","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharma.2023.03.003_bib0420","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/1471-2369-14-167","article-title":"Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: a post-hoc analysis of a prospective study","volume":"14","author":"Prats","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0425","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12882-016-0391-7","article-title":"Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial","volume":"17","author":"Roberts","year":"2016","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0430","first-page":"108","article-title":"Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia","volume":"145","author":"S\u00e1nchez-Gonz\u00e1lez","year":"2015","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.pharma.2023.03.003_bib0435","doi-asserted-by":"crossref","first-page":"e0167146","DOI":"10.1371\/journal.pone.0167146","article-title":"Choice of high-dose intravenous iron preparation determines hypophosphatamia risk","volume":"11","author":"Schaefer","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pharma.2023.03.003_bib0440","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1210\/clinem\/dgab852","article-title":"Risk factors for and effects of persistent and severe hypophosphatemia following ferric carboxymaltose","volume":"107","author":"Schaefer","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharma.2023.03.003_bib0445","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1007\/s11695-020-04544-x","article-title":"High risk of hypophosphatemia in patients with previous bariatric surgery receiving ferric carboxymaltose: a prospective cohort study","volume":"30","author":"Schoeb","year":"2020","journal-title":"Obes Surg"},{"key":"10.1016\/j.pharma.2023.03.003_bib0450","first-page":"67","article-title":"Clinical use of ferric carboxymaltose in patients with solid tumors or haematological malignancies in France","volume":"24","author":"Toledano","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.pharma.2023.03.003_bib0455","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1159\/000327019","article-title":"Effect of intravenous saccharated ferric oxide on serum FGF 23 and mineral metabolism in hemodialysis patients","volume":"33","author":"Takeda","year":"2011","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0460","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.AOG.0000275286.03283.18","article-title":"Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia","volume":"110","author":"Van Wyck","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0465","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1111\/j.1537-2995.2009.02327.x","article-title":"Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia un heavy uterine bleeding: a randomized controlled trial","volume":"49","author":"Van Wyck","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.pharma.2023.03.003_bib0470","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor and phosphate homeostasis in women","volume":"28","author":"Wolf","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.pharma.2023.03.003_bib0475","doi-asserted-by":"crossref","first-page":"e124486","DOI":"10.1172\/jci.insight.124486","article-title":"Randomized trial of intravenous iron-induced hypophosphatemia","volume":"3","author":"Wolf","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharma.2023.03.003_bib0480","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1111\/bcp.14643","article-title":"Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside\u00a0\u2013\u00a0a systematic review and meta-analysis","volume":"87","author":"Schaefer","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0485","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40264-022-01216-w","article-title":"High-dose intravenous iron with either ferric carboxymaltose or ferric derisomaltose: a benefit\u2013risk assessment","volume":"45","author":"Boots","year":"2022","journal-title":"Drug Saf"},{"key":"10.1016\/j.pharma.2023.03.003_bib0490","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1210\/jc.2008-2396","article-title":"FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study","volume":"94","author":"Schouten","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharma.2023.03.003_bib0495","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.26100","article-title":"Parenteral iron therapy and phosphorus homeostasis","volume":"96","author":"Kalantar-Zadeh","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.pharma.2023.03.003_bib0500","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","article-title":"Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease","volume":"23","author":"Wolf","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.pharma.2023.03.003_bib0505","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1210\/jc.2011-1239","article-title":"Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans","volume":"96","author":"Imel","year":"2011","journal-title":"J Clin Endocr Res"},{"key":"10.1016\/j.pharma.2023.03.003_bib0510","doi-asserted-by":"crossref","first-page":"E1146","DOI":"10.1073\/pnas.1110905108","article-title":"Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice","volume":"108","author":"Farrow","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharma.2023.03.003_bib0515","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/ggi.13194","article-title":"Iron deficiency anemia in older adults: a review","volume":"18","author":"Joosten","year":"2018","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.pharma.2023.03.003_bib0520","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s12603-019-1215-9","article-title":"The relationship between nutritional status, anemia and other vitamin deficiencies in the elderly receiving home care","volume":"23","author":"Emiroglou","year":"2019","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.pharma.2023.03.003_bib0525","first-page":"437","article-title":"Anemia in older adults","volume":"98","author":"Lanier","year":"2018","journal-title":"Am Fam Physician"},{"issue":"0304","key":"10.1016\/j.pharma.2023.03.003_bib0530","article-title":"Hypocalc\u00e9mie, hypomagn\u00e9s\u00e9mie et hypophosphat\u00e9mie","volume":"21","author":"Burckhardt","year":"2021","journal-title":"Forum Med Suisse"},{"key":"10.1016\/j.pharma.2023.03.003_bib0535","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.ekir.2019.06.002","article-title":"Strategies for phosphate control in patients with CKD","volume":"4","author":"Carvalho Barreto","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.pharma.2023.03.003_bib0540","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S243462","article-title":"Hypophosphatemia associated with intravenous iron therapies for iron deficiency anemia: a systematic literature review","volume":"16","author":"Glaspy","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.pharma.2023.03.003_bib0545","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: an emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.pharma.2023.03.003_bib0550","doi-asserted-by":"crossref","first-page":"116202","DOI":"10.1016\/j.bone.2021.116202","article-title":"Hypophosphatemia after intravenous iron therapy: comprehensive review of clinical findings and recommendations for management","volume":"254","author":"Schaefer","year":"2022","journal-title":"Bone"},{"key":"10.1016\/j.pharma.2023.03.003_bib0555","unstructured":"US FDA prescribing information for Injectafer. https:\/\/www.access_data.fda.gov\/drugsatfda_docs\/label\/2022\/203565Orig1s019lbl.pdf."},{"key":"10.1016\/j.pharma.2023.03.003_bib0280","first-page":"838","article-title":"Bilan phosphocalcique perturb\u00e9 dans le cadre d\u2019une fragilit\u00e9 osseuse\u00a0: des cl\u00e9s pour le praticien","volume":"13","author":"Aubry-Rozier","year":"2017","journal-title":"Rev Med Suisse"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450923000251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450923000251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:37:18Z","timestamp":1757720238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450923000251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0003450923000251"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2023.03.003","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypophosphor\u00e9mie apr\u00e8s traitement par fer injectable chez l\u2019adulte\u00a0: comparaison entre le carboxymaltose ferrique et l\u2019hydroxyde ferrique-saccharose","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2023.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}